22nd Jan 2026 Plain language summary: ATTRibute-CM study findings on acoramidis treatment in transthyretin amyloid heart disease
28th Nov 2025 How patients and doctors view pulmonary hypertension treatment options: a plain language summary
26th Nov 2025 Plain language summary: real-world tafamidis study in transthyretin amyloid cardiomyopathy (ATTR-CM) patients
28th Aug 2025 Examining empagliflozin’s safety profile across four clinical trials: a plain language summary
28th Aug 2025 Plain language summary: comparing the effects of changing versus continuing blood thinners in people with atrial fibrillation
15th Aug 2025 Plain language summary: examining the effectiveness, safety, and longevity of a new bioprosthetic aortic valve replacement
17th Jul 2025 Plain language summary: the long-term benefits and safety of evinacumab treatment for people with a severe inherited cholesterol disorder
25th Jun 2025 Treating pulmonary arterial hypertension with oral treprostinil tablets (Orenitram): a plain language summary
20th Jun 2025 Plain language summary: how aficamten performed in the SEQUOIA-HCM trial for patients with symptomatic obstructive hypertrophic cardiomyopathy
27th May 2025 How tafamidis affects lifespan in people with transthyretin amyloid heart disease: plain language summary
20th May 2025 Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary
13th Feb 2025 Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary
17th Jan 2025 Exploring the benefits of transcatheter aortic valve replacement for severe symptomatic aortic stenosis: a plain language summary
23rd Sep 2024 Impact of extended tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM)
22nd Jan 2024 The effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes: a plain language summary
16th Nov 2023 Plain language summary of the EMPEROR-Preserved : drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction
15th Nov 2023 A plain language summary of the EMPEROR-Reduced study: drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction
13th Sep 2023 The effect of vibegron on the blood pressure and heart rate in people with overactive bladder: a plain language summary
20th Jul 2023 A Plain Language Summary on the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease
7th Jun 2023 Plain Language Summary: the ORION-10 and ORION-11 studies look at how well inclisiran works in people with high cholesterol
12th Apr 2023 Plain Language Summary: long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy caused by a faulty LMNA gene
11th Apr 2023 Plain Language Summary: long-term survival in people being treated with tafamidis for transthyretin amyloid cardiomyopathy
27th Feb 2023 Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene
20th Sep 2022 Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
16th Mar 2022 How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary
4th Mar 2022 Is the sodium in sodium oxybate a risk for heart health? A plain language summary of publication
15th Nov 2021 Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary
21st May 2021 A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy
